ABHD6抗体;ABHD6 Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P12797(ABHD6 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P12797(ABHD6 Antibody) at dilution 1/35. (Original magnification: ×200)    

  
  

ABHD6 (α/β-hydrolase domain-containing protein 6) is a serine hydrolase enzyme involved in lipid metabolism, particularly the hydrolysis of 2-arachidonoylglycerol (2-AG), a key endocannabinoid signaling molecule. It regulates endocannabinoid signaling pathways that influence synaptic plasticity, neuroinflammation, and energy homeostasis. ABHD6 antibodies are essential tools for detecting, quantifying, and studying the expression, localization, and function of this enzyme in biological systems.

These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and flow cytometry to investigate ABHD6's role in neurological disorders (e.g., epilepsy, neuropathic pain), metabolic diseases (e.g., obesity, diabetes), and cancer. Studies highlight ABHD6's dual role in degrading 2-AG and modulating lysophosphatidylserine metabolism, linking it to inflammatory responses and tumor progression.

ABHD6-specific antibodies also support drug discovery efforts, as the enzyme is a therapeutic target for conditions like metabolic syndrome and neurodegenerative diseases. Monoclonal and polyclonal variants are available, with validation emphasizing specificity to avoid cross-reactivity with homologous hydrolases (e.g., ABHD12). Recent research explores ABHD6 inhibition to enhance endocannabinoid signaling, underscoring the antibody's utility in both basic research and preclinical development.